Infantix, a medical device engineered in Cuba for detecting hearing disorders in newborns, has received the necessary health registration for use in Colombia, announced the business group BioCubaFarma via their social media platforms.
According to the official Cuban newspaper, Granma, Infantix serves as a neonatal screening system that records and analyzes "automatic auditory brainstem responses and otoacoustic emissions." Furthermore, it "includes an innovative stimulation methodology through both air and bone conduction, which aids in distinguishing between transient conductive hearing losses and permanent ones due to neural damage."
This device, developed at the Center for Neurosciences of Cuba (CNeuro), plays a crucial role in the "early identification of disabilities virtually from the moment a child is born." In 2024, 22 units of Infantix were produced, as reported by Cubadebate a few months ago. Of these, ten units had been deployed in Cuban hospitals, while another ten were introduced through a project with MediCuba Switzerland.
As part of the project called Adelante 2, aimed at international markets, Infantix has also been made available to the Neurodevelopment Unit at the National Autonomous University of Mexico in Querétaro and the Hospital del Niño y la Mujer in the same country.
Pharmaceutical Exports to Brazil
In a recent development, BioCubaFarma signed a biotechnology and pharmaceutical cooperation agreement with the municipality of Maricá, located in the state of Rio de Janeiro, Brazil. This agreement will facilitate the joint production of Cuban medicines in the South American nation.
According to the Cuban News Agency, the agreement was finalized during a meeting in Havana between Cuban authorities and a Brazilian delegation led by the Maricá City Hall and its Institute of Technology and Innovation. The goal is to strengthen ties in the biopharmaceutical sector and establish new export routes for medical technology developed on the island.
Frequently Asked Questions about Infantix and BioCubaFarma's International Efforts
What is the purpose of the Infantix device?
Infantix is designed to detect hearing disorders in newborns through advanced screening systems that analyze auditory brainstem responses and otoacoustic emissions.
Where has Infantix been introduced internationally?
Infantix has been introduced to the Neurodevelopment Unit at the National Autonomous University of Mexico in Querétaro and the Hospital del Niño y la Mujer, as part of its international market expansion efforts.
What is the significance of BioCubaFarma's agreement with Brazil?
The agreement enables the joint production of Cuban pharmaceuticals in Brazil, strengthening the biopharmaceutical collaboration between the two countries and opening new avenues for Cuban medical technology exports.